Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 14/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349389 | 0.90 | CASP3 (0.50) | GRM5HPGDSPAK1 | |
| SCHEMBL8271768 | 0.89 | PAK1 (0.49) | CNR2GRM5HPGDSPAK1 | |
| SCHEMBL5657638 | 0.89 | HPGDS (0.47) | MAPK1MKNK1CNR2HPGDSPAK1 | |
| SCHEMBL4310748 | 0.89 | HPGDS (0.47) | MAPK1MKNK1CNR2HPGDSPAK1 | |
| SCHEMBL8271761 | 0.85 | CNR2 (0.47) | HTTCNR2HPGDSPAK1 | |
| SCHEMBL8271778 | 0.84 | MAPK1 (0.43) | MAPK1HTTMKNK1CNR2HPGDS | |
| SCHEMBL14349470 | 0.84 | PAK1 (0.49) | MKNK1CNR2HPGDSPAK1 | |
| SCHEMBL8271758 | 0.84 | PAK1 (0.49) | HTTCNR2HPGDSPAK1 | |
| SCHEMBL14349390 | 0.83 | GRIN2B (0.52) | HTTCNR2HPGDSPAK1 | |
| SCHEMBL14349391 | 0.81 | PAK1 (0.48) | MAPK1HPGDSPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | GRIN2B, GRIN2A, GRIN1 | MAPK1 2419/4885HTT 662/4885MKNK1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.